Colorectal Cancer Metastasis
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (20 February 2023) | Viewed by 28438
Special Issue Editors
Interests: cancer genetics; gastro-intestinal oncology; oligo-metastatic disease; molecular oncology; precision oncology
Special Issues, Collections and Topics in MDPI journals
Interests: noncoding RNAs; micro-RNAs; prostate cancer; nanotechnological delivery of anticancer drugs and nucleic acids; diagnostic markers in cancer; urotensin II receptor; next-generation sequencing; predictive markers of response; circulating tumor cells
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Excluding some very rare inherited forms, colorectal cancer (CRC) is a multigenic disease. The study on correlations between genotype and phenotype in metastatic CRC (mCRC) requires a considerable multidisciplinary effort (oncologist, molecular biologist, biostatistician, geneticist, bioinformatician, etc.), and it is extremely challenging because of the great genetic heterogeneity of tumor progeny in space and time. The identification of driver mutations that significantly influence the biological behavior of cancer cells represents a further difficulty. However, information from such genotype/phenotype correlations may be crucial for identifying new key driver genes and for improving the knowledge of gene function itself. The increasing availability of targeted and whole exome DNA sequencing techniques has allowed researchers to start the exploration of (epi)genotype/phenotype correlations in CRC. These molecular changes involve nucleic acids, both intratumoral and circulating, and include not only gene mutations but also epigenetic modifications such as noncoding RNAs and DNA methylation patterns. Furthermore, the continuous refinement of methods to take and assess tumor nucleic acids (both DNA and RNA), including so-called “liquid biopsy”, makes it possible to follow the genetic changes of tumor cells during the evolution of cancer and after the different treatments administered in the different lines of therapy. In this way, tumor plasticity can be studied and defined in each single patient, correlating it with the clinical outcome and allowing to achieve the final aim of precision medicine, detecting prognostic markers and molecular targets for the design of the most adequate treatment.
The present research topic in mCRC has been established to prompt researchers to provide insights into:
- Prognostic and predictive correlations of specific cancer genetics;
- Emerging methods to make correlations between (epi)genotype (including gene expression and mutation, noncoding RNAs and DNA methylation status) and phenotype (metastatic behavior);
- Novel techniques and novel models to interpret genetic CRC behavior;
- Novel biomarkers and biologic surrogates to study cancer plasticity from primary to metastatic lesions.
Articles consisting exclusively of bioinformatics or computational analyses of public databases will not be accepted. Analyses and studies coming from real practice and independent clinical cohorts of patients are the preferred target of this research topic. Reviews are also appreciated.
Prof. Dr. Alessandro Ottaiano
Prof. Dr. Michele Caraglia
Dr. Luisa Circelli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- genetics
- epigenetics
- metastases
- prognosis
- cancer evolution
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.